BIOPHARMA
By
Will the European Commission’s New Health Policy Package Accelerate Biotech, AI, and Medical Device Innovation?
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and resilience across the…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for Adults?
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Are Galux and Boehringer Ingelheim Pioneering AI in Precision Protein Design?
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics, has entered a…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal Zone Lymphoma Patients?
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
Can Ainnocence’s Causal AI Platform Redefine Drug Discovery Value as Pharma Expands AI Partnerships?
Strategic Overview Ainnocence is carving out a differentiated role in AI-driven drug discovery by emphasizing causal, mechanism-oriented artificial…
Can Standigm’s Knowledge-Graph AI Outperform AI Peers Like Exscientia and Insilico as Global Pharma Commits $500M+ to Collaborative Discovery?
Strategic Overview Standigm is emerging as a distinctive force in AI-driven drug discovery by grounding its platform in…
